Authors


Holly Jackson

Latest:

The Case for Response Adaptive Trial Design for Rare Diseases

As pharma businesses shift their focus away from ‘blockbusters’ to treatments for rare diseases, clinical trial design must also go through a period of change and should consider response-adaptive over traditional randomized controlled trial designs.


Jonathan Seltzer, MD, MBA, MA

Latest:

Moving From Compliance to Competency: A Harmonized Core Competency Framework for the Clinical Research Professional

Medicines development and clinical research are among the most heavily regulated activities on a global basis.


David Martin

Latest:

MyStudies Platform Brings Patient Experience to Drug Development

MyStudies, introduced by the FDA, bridges data streams to real world evidence by facilitating the collection of real-world data directly from patients in conjunction with a variety of data sources.





Valdo Arnera

Latest:

Demystifying Submissions of eCOA Documentation for Ethics Review: Are We Making Submissions More Difficult than Necessary?

Examining how to optimizing the time and effort of Ethics Committees to efficiently and effectively fulfill their human subjects protection remit.






Yakov Datsenko, MD

Latest:

Leading Clinical Projects

A survey of clinical research professionals asked: What makes you a successful project leader?


Irina Petrova

Latest:

Key Cost Drivers in Clinical Research: Guide to Successful Budgeting

It's almost impossible to map out study budgets with absolute precision. Planning for the unexpected costs, such as those associated with slow enrollment, protocol amendments, and other contingencies—is vital.


Linda Reuter

Latest:

The Revised Common Rule and New “Concise Summary” Requirements

Linda Reuter, CIP, Director of BRANY IRB, discusses the Revised Common Rule that now requires informed consent to begin with a concise and focused presentation of key information that will help the patient better understand the reasons why they might or might not want to participate in the research.


Mohamed El Malt

Latest:

Acquiring Medical Guidance in Clinical Trials

A critical part of clinical trial conduct is providing medical guidance by the responsible medical monitor to investigative sites and various operations team members, including, but not limited to, clinical research associates and clinical study managers.




Sandra Pagnussat

Latest:

Five Strategies for Conducting Successful Pediatric Trials

Sandra Pagnussat, of QPS, explores strategies to help combat the unique set of challenges that pediatric trials present.


Chris Barker

Latest:

Biases in Characterization of Oncology Trials for Policy Decisions

Chris Barker, an Independent Statistical Consultant, discusses the differences and biases in summaries obtained from a database called PDQ vs. CTG.


ThoughtSphere

Latest:

Analytics and RBM for Clinical Trial Oversight

Learn the benefits of an approach that focuses on risks to the most critical data elements and processes of each study and how effective data integration is the foundation.


Basheer Hawwash

Latest:

Using AI & Machine Learning to Better Understand Data and Manage Risk

Basheer Hawwash, Principal Data Scientist at Remarque Systems Inc., writes of the potential artificial intelligence, more specifically machine learning, has to transform clinical trials.


Audra D. Catalano, MA, MBA

Latest:

The Use of a Single Center, Multi-Location Research Structure For Participation in Large Clinical Trials: The Cleveland Clinic Model

As funding for clinical research trials decreases and sponsors of clinical studies are under increasingly stringent timelines to obtain FDA approval and get new therapies to market, the need increases for well-managed, efficient, and effective clinical trial sites.


Kevin Pounds

Latest:

eClinical Technology Considerations for Cell and Gene Therapy Studies: Case Study Snapshots of Personalized Medicine

With the world of gene therapy still rapidly evolving, an Interactive Response Technology system might help a sponsor navigate new and complex steps throughout the supply chain.


Dan Pavitt

Latest:

eClinical Technology Considerations for Cell and Gene Therapy Studies: Case Study Snapshots of Personalized Medicine

With the world of gene therapy still rapidly evolving, an Interactive Response Technology system might help a sponsor navigate new and complex steps throughout the supply chain.


Irfan Khan

Latest:

Patient Experience Comes to Drug Development

The transformation in patient perceptions will only happen when the five million Americans who’ve already participated in clinical trials can directly share their experiences with the next five million people considering participating.


Susan M. Manzi, MD

Latest:

Addressing a Critical Need for the Global Lupus Community

Global experts collaborate to form the Addressing Lupus Pillars for Health Advancement (ALPHA) Project in order to combat challenges in lupus drug development.


Alex Neumeister

Latest:

Pharma Companies Use AI to Advance Drug Development

BioXcel Therapeutics Executives, Vimal Mehta and Vince O’Neill, discuss how they are actively using artificial intelligence to discover advanced therapies in CNS and oncology.


Michael Keens

Latest:

Why Patient-centric Clinical Trials Are Easier Said Than Done

Michael Keens, COO of Firma Clinical, explores the beginning of patient centricity, common misconceptions related to its implementation, and offers steps to improve the ability to achieve patient centricity within drug development.


Genevieve Depresseux

Latest:

A New Model to Support Leadership Skills of Principal Investigators

Taking a closer look at the skills expected from the Principal Investigator beyond the expected technical skills.


Andrew A Parsons

Latest:

A New Model to Support Leadership Skills of Principal Investigators

Taking a closer look at the skills expected from the Principal Investigator beyond the expected technical skills.

© 2024 MJH Life Sciences

All rights reserved.